Intellipharmaceutics International Inc trades with the ticker IPCI on the TSX and is in the Biotechnology industry.
Overview
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.
Looking to invest in Intellipharmaceutics International Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.
Table of Contents
show
IPCI.TO Stock Price and Key Stats
ETF Key Stats
Exchange: TSX
Market Cap : $2.647MM
PE Ratio:
Price: 0.08 (Updated: 3/12/2024 0:47:16)
Intellipharmaceutics International Inc (IPCI) vs Competitors in Biotechnology
Lets see how IPCI.TO stacks up against others in the Biotechnology asset management industry. We have identified its main peers as:Aeterna Zentaris Inc, Aptose Biosciences Inc, BELLUS Health Inc, Fennec Pharmaceuticals Inc, IMV Inc
.Biotechnology Industry Comparisons
| Company | Market Cap ($MM) | P/E Ratio | EV/EBITDA | Dividend Yield |
|---|---|---|---|---|
| Aeterna Zentaris Inc (AEZS) | $12.674 | N/A | 1.709 | N/A% |
| Aptose Biosciences Inc (APS) | $33.927 | N/A | -0.231 | N/A% |
| BELLUS Health Inc (BLU) | $2,470.298 | N/A | -16.428 | 0.0% |
| Fennec Pharmaceuticals Inc (FRX) | $352.565 | N/A | -21.793 | N/A% |
| IMV Inc (IMV) | $13.117 | N/A | -0.843 | 0.0% |
EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield
Comparisons within Biotechnology
- Intellipharmaceutics International Inc (IPCI) vs Aeterna Zentaris Inc (AEZS)
- IPCI has higher EPS (-0.12 vs -6.47). AEZS and IPCI both have P/E’s under 0.
- Intellipharmaceutics International Inc (IPCI) vs Aptose Biosciences Inc (APS)
- IPCI has higher EPS (-0.12 vs -10.45). APS and IPCI both have P/E’s under 0.
- Intellipharmaceutics International Inc (IPCI) vs BELLUS Health Inc (BLU)
- IPCI has higher EPS (-0.12 vs -0.96). BLU provides dividends, while IPCI does not. BLU and IPCI both have P/E’s under 0.
- Intellipharmaceutics International Inc (IPCI) vs Fennec Pharmaceuticals Inc (FRX)
- IPCI has higher EPS (-0.12 vs -1.01). FRX and IPCI both have P/E’s under 0.
- Intellipharmaceutics International Inc (IPCI) vs IMV Inc (IMV)
- IPCI has higher EPS (-0.12 vs -6.11). IMV provides dividends, while IPCI does not. IMV and IPCI both have P/E’s under 0.
Our Recommendation: Review
May not stand out on key metrics or lacks sufficient data for a strong recommendation.
How to Buy IPCI stock on the TSX
You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:| Image | Product Title | Features | Price |
|---|---|---|---|
Editor's Choice  |
| Get $25 Signup Bonus | |
Reliable Pick  |
| Get $50 Free Stock Trades |
